P86 Stock Overview
Engages in the research and development of therapeutic products for human use in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Paradigm Biopharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.18 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.14 |
| Beta | 0.99 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 23.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| P86 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.7% | 1.2% | 0.8% |
| 1Y | n/a | -16.0% | 6.1% |
Return vs Industry: Insufficient data to determine how P86 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how P86 performed against the German Market.
Price Volatility
| P86 volatility | |
|---|---|
| P86 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: P86 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine P86's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Paul Rennie | www.paradigmbiopharma.com |
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Paradigm Biopharmaceuticals Limited Fundamentals Summary
| P86 fundamental statistics | |
|---|---|
| Market cap | €64.31m |
| Earnings (TTM) | -€42.93m |
| Revenue (TTM) | €26.16k |
2,458x
P/S Ratio-1.5x
P/E RatioIs P86 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P86 income statement (TTM) | |
|---|---|
| Revenue | AU$42.05k |
| Cost of Revenue | AU$11.47k |
| Gross Profit | AU$30.58k |
| Other Expenses | AU$69.03m |
| Earnings | -AU$69.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 72.73% |
| Net Profit Margin | -164,092.68% |
| Debt/Equity Ratio | 0% |
How did P86 perform over the long term?
See historical performance and comparison